(IN BRIEF) The U.S. Food and Drug Administration (FDA) has granted approval for Dupixent® (dupilumab) to treat pediatric patients aged 1 to 11 years, weighing at least 15 kg, who suffer from eosinophilic esophagitis (EoE). Dupixent is now the first … Read the full press release
Posted in Business, Education, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged dupilumab, Dupixent, Eosinophilic Esophagitis (EoE) Treatment, FDA approval, George D. Yancopoulos, Naimish Patel, pediatric, Regeneron, Sanofi
(PRESSEMITTEILUNG) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert , hat angekündigt, dass das Unternehmen auf seinem Immunology Investor Event, das am Dienstag, den 29. März ab 14:00 Uhr … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronisch entzündliche Erkrankungen, chronisch obstruktive Lungenerkrankung, COPD, dupilumab, Dupixent®, Immunologie, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetische Zytokine, TAILORED COVALENCY™, Typ-2-Entzündung
(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that the company will provide an update on its Immunology strategy at its Immunology Investor Event, which is taking place … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronic inflammatory diseases, Chronic obstructive pulmonary disease, COPD, dupilumab, Dupixent, immunology, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetic cytokines, Tailored Covalency®, type 2 inflammation
Dupixent ist das erste und einzige Medikament mit positiven Phase-3-Ergebnissen bei Prurigo nodularis, was den potenziellen Nutzen einer gezielten Behandlung von IL-4 und IL-13, zentralen Treibern von Typ-2-Entzündungen, zur Behandlung von Juckreiz und Hautläsionen bestätigt Die Daten bestätigen die Ergebnisse … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science, Technology
Tagged anhaltender Juckreiz, asthma, Atemwegserkrankungen, atopische Dermatitis, dermatologische Erkrankungen, dupilumab, Dupixent, entzündliche Hauterkrankung, extremer Juckreiz, George D. Yancopoulos, Hauterkrankungen, Hautläsionen, Knötchen, Naimish Patel, prurigo nodularis, Regeneron, unerträglicher Juckreiz
Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions Data confirm results … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged asthma, atopic dermatitis, CRSwNP, dermatological diseases, dupilumab, Dupixent, extreme itch, George D. Yancopoulos, inflammatory skin disease, Naimish Patel, nodules, persistent itch, prurigo nodularis, Regeneron, respiratory diseases, skin diseases, skin lesions, unbearable itch
First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline Pivotal program is first with a biologic to show consistent reductions … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged dupilumab, Sanofi, steroid-dependent asthma
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?